Ogawa et al. used both xenograft models and human tissue samples to demonstrate its upregulation, together with its ligand ephrin-A1, in the vasculature of mammary tumors, proposing EPHA2 as a possible anti-angiogenic therapeutic target [24]. The gene discussed is EFNA1; the disease is breast cancer.